Prognostic impact of atrial rhythm and dimension in patients with structural heart disease undergoing cardiac sympathetic denervation for ventricular arrhythmias.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
05 2020
Historique:
received: 26 08 2019
pubmed: 15 12 2019
medline: 17 6 2021
entrez: 15 12 2019
Statut: ppublish

Résumé

Cardiac sympathetic denervation (CSD) is a promising treatment for patients with structural heart disease (SHD) and refractory ventricular tachyarrhythmias (VTs). The effect of CSD on atrial rhythm as well as the prognostic impact of atrial arrhythmias (AAs) or left atrial volume index (LAVI) on CSD outcome are unknown. The goals of this study were to evaluate the impact of AAs and LAVI on CSD outcome and to assess changes in AAs burden and in atrial pacing after CSD. Patients with SHD undergoing CSD for VTs were analyzed. Hazards models were built to assess predictors of sustained VT/implantable cardioverter-defibrillator (ICD) shock recurrences and death/orthotopic heart transplant (OHT). Changes before vs after CSD were assessed using ICD, clinical, and echocardiographic data. A drug index was devised to correct for medication use. Between 2009 and 2018, 91 patients (mean age 56 ± 13 years; mean left ventricular ejection fraction 34% ± 14%; 47% with a history of AAs) underwent left CSD (16%) or bilateral CSD (BCSD). The median follow-up was 14 months (interquartile range 4-37 months). Using multivariable analysis, neither LAVI nor AAs were associated with recurrences; LAVI was an independent predictor of death/OHT. AAs burden did not change after BCSD, but atrial pacing increased from a median of 28% to 72% (P < .01). Left ventricular end-diastolic diameter slightly increased; however, sustained VT/ICD shocks were reduced. In patients with SHD undergoing CSD, LAVI predicts death/OHT. AAs burden, already low at baseline, was unchanged after BCSD, while the need for atrial pacing increased, suggesting an impact of BCSD on sinus node chronotropism.

Sections du résumé

BACKGROUND
Cardiac sympathetic denervation (CSD) is a promising treatment for patients with structural heart disease (SHD) and refractory ventricular tachyarrhythmias (VTs). The effect of CSD on atrial rhythm as well as the prognostic impact of atrial arrhythmias (AAs) or left atrial volume index (LAVI) on CSD outcome are unknown.
OBJECTIVES
The goals of this study were to evaluate the impact of AAs and LAVI on CSD outcome and to assess changes in AAs burden and in atrial pacing after CSD.
METHODS
Patients with SHD undergoing CSD for VTs were analyzed. Hazards models were built to assess predictors of sustained VT/implantable cardioverter-defibrillator (ICD) shock recurrences and death/orthotopic heart transplant (OHT). Changes before vs after CSD were assessed using ICD, clinical, and echocardiographic data. A drug index was devised to correct for medication use.
RESULTS
Between 2009 and 2018, 91 patients (mean age 56 ± 13 years; mean left ventricular ejection fraction 34% ± 14%; 47% with a history of AAs) underwent left CSD (16%) or bilateral CSD (BCSD). The median follow-up was 14 months (interquartile range 4-37 months). Using multivariable analysis, neither LAVI nor AAs were associated with recurrences; LAVI was an independent predictor of death/OHT. AAs burden did not change after BCSD, but atrial pacing increased from a median of 28% to 72% (P < .01). Left ventricular end-diastolic diameter slightly increased; however, sustained VT/ICD shocks were reduced.
CONCLUSION
In patients with SHD undergoing CSD, LAVI predicts death/OHT. AAs burden, already low at baseline, was unchanged after BCSD, while the need for atrial pacing increased, suggesting an impact of BCSD on sinus node chronotropism.

Identifiants

pubmed: 31837474
pii: S1547-5271(19)31099-9
doi: 10.1016/j.hrthm.2019.12.007
pmc: PMC7196021
mid: NIHMS1546480
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

714-720

Subventions

Organisme : NHLBI NIH HHS
ID : DP2 HL142045
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL125730
Pays : United States
Organisme : NIH HHS
ID : OT2 OD023848
Pays : United States

Informations de copyright

Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Références

J Physiol. 2016 Jul 15;594(14):3877-909
pubmed: 27098459
Nat Commun. 2019 Apr 26;10(1):1944
pubmed: 31028266
Heart Rhythm. 2016 Nov;13(11):2111-2117
pubmed: 27353237
J Am Coll Cardiol. 2014 Feb 18;63(6):493-505
pubmed: 24291276
J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220
pubmed: 29097296
Heart Rhythm. 2014 Mar;11(3):360-6
pubmed: 24291775
Heart Rhythm. 2016 Jan;13(1):62-9
pubmed: 26341607
Circ Arrhythm Electrophysiol. 2018 Dec;11(12):e006730
pubmed: 30562104
J Physiol. 2016 Jul 15;594(14):3911-54
pubmed: 27114333
J Am Heart Assoc. 2018 Nov 20;7(22):e010156
pubmed: 30554547
J Am Coll Cardiol. 2015 Mar 31;65(12):1231-1248
pubmed: 25814231
Eur J Heart Fail. 2006 Jan;8(1):38-45
pubmed: 16115798
J Am Coll Cardiol. 2017 Jun 27;69(25):3070-3080
pubmed: 28641796
Circ Res. 1979 May;44(5):637-45
pubmed: 428059
Anesthesiology. 1978 Feb;48(2):139-41
pubmed: 655444
J Cardiovasc Electrophysiol. 2019 Sep;30(9):1499-1507
pubmed: 31199536
JCI Insight. 2017 Sep 21;2(18):
pubmed: 28931760

Auteurs

Veronica Dusi (V)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Molecular Medicine, Section of Cardiology, University of Pavia; Arrhythmia and Electrophysiology and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Julie M Sorg (JM)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jeffrey Gornbein (J)

Departments of Medicine and Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jean Gima (J)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jane Yanagawa (J)

Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jay M Lee (JM)

Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Natalia Vecerek (N)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Marmar Vaseghi (M)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jason S Bradfield (JS)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Gaetano M De Ferrari (GM)

Department of Molecular Medicine, Section of Cardiology, University of Pavia; Arrhythmia and Electrophysiology and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Kalyanam Shivkumar (K)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

Olujimi A Ajijola (OA)

UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: oajijola@mednet.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH